SNFGE SNFGE
 
Thématique :
- Cancer colorectal (CCR)
Originalité :
Intermédiaire
Solidité :
Très solide
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Professeur Sylvain MANFREDI
Coup de coeur :
 
 
Digestive and Liver Disease
  2017/03  
 
  2017 Mar;49(3):308-311  
  doi: 10.1016/j.dld.2016.09.015.  
 
  Additional mailing phase for FIT after a medical offer phase: The best way to improve compliance with colorectal cancer screening in France  
 
  Piette C, Durand G, Bretagne JF, Faivre J  
  https://www.ncbi.nlm.nih.gov/pubmed/27810401  
 
 

Abstract

BACKGROUND:

Compliance with colorectal cancer screening is critical to its effectiveness. The organisation of the mass screening programme in France has recently been modified with no evaluation of the consequences.

AIMS:

To evaluate the impact of the way the screening test is delivered on compliance.

PATIENTS AND METHODS:

During the first six months of the screening campaign (Ille-Vilaine, Brittany), general practitioners were asked to propose a faecal immunochemical test (FIT), OC-Sensor, to individuals at average risk for colorectal cancer (n=152,097). A subset of non-participants in the medical phase (n=13,071) was randomly chosen to receive a reminder that included the screening test or a simple postal reminder without the screening test.

RESULTS:

Compliance was 31% if the screening test was proposed during a medical consultation. In non-participants during the medical phase, it was 45% in those receiving both a reminder and the screening test and 28% amongst those receiving a simple reminder. An estimated overall participation rate of 54% can be expected if non-participants in the medical phase are sent a reminder together with the screening test.

CONCLUSION:

In France, a compliance rate above the minimum uptake rate of 45% recommended by European Union experts can be achieved if the FIT is mailed to non-participants after the medical free-offer phase.

 
Question posée
 
L’envoi du test de dépistage aux individus permet-il d’augmenter la participation au dépistage de masse du cancer colorectal?
 
Question posée
 
Cette relance avec test, abandonnée lors du passage de l’Hémoccult® au test immunologique, permet d’obtenir une participation supérieure à 50%.
 
Commentaires

A lire aussi le commentaire de JC Saurin dans le même numéro.

 
www.snfge.org